



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Gabriella Campadelli-Fiume,  
✉ [gabriella.campadelli@unibo.it](mailto:gabriella.campadelli@unibo.it)  
Tatiana Gianni,  
✉ [tatiana.gianni3@unibo.it](mailto:tatiana.gianni3@unibo.it)

<sup>†</sup>These authors have contributed equally to this work and share last authorship

RECEIVED 05 June 2024  
ACCEPTED 06 June 2024  
PUBLISHED 25 June 2024

CITATION  
Vannini A, Parenti F, Forghieri C, Barboni C, Zaghini A, Campadelli-Fiume G and Gianni T (2024), Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers.  
*Front. Mol. Biosci.* 11:1444446.  
doi: 10.3389/fmolb.2024.1444446

COPYRIGHT  
© 2024 Vannini, Parenti, Forghieri, Barboni, Zaghini, Campadelli-Fiume and Gianni. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers

Andrea Vannini<sup>1,2</sup>, Federico Parenti<sup>1</sup>, Cristina Forghieri<sup>1</sup>,  
Catia Barboni<sup>3</sup>, Anna Zaghini<sup>3</sup>, Gabriella Campadelli-Fiume<sup>1\*†</sup>  
and Tatiana Gianni<sup>1\*†</sup>

<sup>1</sup>Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy, <sup>2</sup>Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy, <sup>3</sup>Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy

## KEYWORDS

oncolytic virus, oncolytic herpes simplex virus, retargeting, nectin4, anti-cancer vaccine, immunotherapy, pancreas carcinoma, triple negative breast cancer

## A Corrigendum on Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers

by Vannini A, Parenti F, Forghieri C, Barboni C, Zaghini A, Campadelli-Fiume G and Gianni T (2023). *Front. Mol. Biosci.* 10:1149973. doi: 10.3389/fmolb.2023.1149973

In the published article, the **Reference** for Lopez and Olive, 2020 was incorrectly written as “Lopez, M., and Olive, D. (2020). Antibodies having specificity to nectin-4 and uses thereof. Google Patents”. It should be “Lopez, M. (2018) Antibodies having specificity to nectin-4 and uses thereof. Google Patents.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.